[ { "id": 734, "name": "One Codex", "slug": "one-codex", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5eedcdf8d152fac7180dc5402647f58cd164448a.png", "website": "https://www.onecodex.com", "all_locations": "Boston, MA, USA; San Francisco, CA, USA", "long_description": "One Codex is a data platform for applied microbial genomics, enabling new and valuable applications in clinical diagnostics, food safety, and biosecurity. Acquired by Invitae (NVTA) in February 2021. Spun out as an independent company in September 2022.", "one_liner": "Data platform for metagenomics and the microbiome.", "team_size": 16, "industry": "Healthcare", "subindustry": "Healthcare -> Healthcare IT", "launched_at": 1401532729, "tags": [ "Biotech", "Diagnostics", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2014", "status": "Acquired", "industries": [ "Healthcare", "Healthcare IT" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/one-codex", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2014/one-codex.json", "year_founded": 2014, "city": "Boston", "country": "US", "linkedin_url": "", "x_url": "https://twitter.com/onecodex", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/one-codex", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/5eedcdf8d152fac7180dc5402647f58cd164448a.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 1831, "full_name": "Nick Greenfield", "title": "Founder", "founder_bio": "Founded One Codex (YC S14), the leading microbial genomics data platform, acquired by Invitae (NVTA) in February 2021 and spun out via an employee buyout in late 2022. VP of Product & Tech (Biosecurity) at Ginkgo Bioworks 2022-2023 (DNA, also YC S14). Reformed management consultant turned software, data, and bio nerd. Skier, cheese-lover, Vermonter, based in VT and Cambridge MA.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/nickgreenfield/", "x_url": "https://twitter.com/boydgreenfield", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/f42aeac5527d4a0c4cce0950a5a86a60c323588c.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1014, "name": "Luminist Labs", "slug": "luminist-labs", "former_names": [ "Luminist" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/b2a824d7b13f5cb87d6f2567fb9307570a0c1d46.png", "website": "http://luministlabs.com", "all_locations": "New York City, NY, USA", "long_description": "Luminist developed a non-invasive diagnostic test for the early detection and staging of liver fibrosis and non-alcoholic steatohepatitis (NASH). Luminist was acquired in 2020 by DiscernDx.", "one_liner": "Diagnostic platform for early detection of liver disease", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1447311916, "tags": [ "Medical Devices", "Diagnostics", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2016", "status": "Acquired", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/luminist-labs", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2016/luminist-labs.json", "year_founded": 2015, "city": "New York City", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/luminist", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/b2a824d7b13f5cb87d6f2567fb9307570a0c1d46.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 103004, "full_name": "Storm Stillman", "title": "Founder/CEO", "founder_bio": "Co-founder and CEO of Luminist Labs (Acquired by DiscernDx)\nCurrently CEO @ Curebase (S18)", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/ecoa", "x_url": "https://twitter.com/StormStillman", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/e18d2a6b6c07645bafa74bc626b5d56b949ed009.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1109, "name": "BillionToOne", "slug": "billiontoone", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/7374f48e30f2dabadb3413903af69fcda589d67f.png", "website": "https://www.billiontoone.com", "all_locations": "San Francisco, CA, USA; Menlo Park, CA, USA", "long_description": "BillionToOne has developed a DNA molecular counter that increases the cell-free DNA diagnostics resolution by over 1,000 fold, which unlocks transformative improvements in prenatal screening and liquid biopsy for cancers. Unity Screen, BillionToOne's commercially available non-invasive prenatal test (NIPT), is the only NIPT that can assess fetal risk for both recessive conditions and aneuploidies from maternal blood. UNITY Screen continues to grow exponentially and is on its path to becoming the next standard-of-care, with an increasing number of publications showing its accuracy and advantages over other screening methods. We have also recently used our molecular counting technology to develop liquid biopsy tests, which have the potential to completely transform oncology care.", "one_liner": "The genetic testing platform detecting and measuring disease.", "team_size": 300, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1453416611, "tags": [ "Diagnostics", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Summer 2017", "status": "Public", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/billiontoone", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2017/billiontoone.json", "year_founded": 2016, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/billiontoone/", "x_url": "https://twitter.com/billiontooneinc?lang=en", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/billiontoone", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/7374f48e30f2dabadb3413903af69fcda589d67f.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Jared Friedman", "url": "https://www.ycombinator.com/people/jared-friedman" }, "founders": [ { "user_id": 113037, "full_name": "Oguzhan Atay", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/oatay", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/bc8f1560f5c3e5e466f3af42f1115b49ae251798.jpg" }, { "user_id": 108548, "full_name": "David Tsao", "title": "Founder/CTO", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/davidtsao", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/ff881934f71e506851b4ce1720adb400b739d98b.jpg" } ], "jobs": [ { "id": 90768, "title": "Senior Software Engineer, Digital Experiences (Prenatal)", "url": "https://www.ycombinator.com/companies/billiontoone/jobs/9ZwkJry-senior-software-engineer-digital-experiences-prenatal", "location": "Menlo Park, CA, US", "type": "Full-time", "role": "Engineering", "role_type": "Full stack", "salary_range": "$190K - $211K", "equity_range": "", "experience": "6+ years", "visa": "US citizen/visa only", "skills": [ "Amazon Web Services (AWS)", "Django", "Python", "React", "TypeScript" ] }, { "id": 90769, "title": "Senior Software Engineer, Prenatal", "url": "https://www.ycombinator.com/companies/billiontoone/jobs/VT6hjtG-senior-software-engineer-prenatal", "location": "Menlo Park, CA, US", "type": "Full-time", "role": "Engineering", "role_type": "Backend", "salary_range": "$190K - $211K", "equity_range": "", "experience": "6+ years", "visa": "US citizen/visa only", "skills": [ "Amazon Web Services (AWS)", "Django", "Python", "React", "TypeScript", "Heroku", "Kafka" ] }, { "id": 93975, "title": "Senior AI Engineer I", "url": "https://www.ycombinator.com/companies/billiontoone/jobs/1dIzNNO-senior-ai-engineer-i", "location": "Menlo Park, CA", "type": "Full-time", "role": "Engineering", "role_type": "Full stack", "salary_range": "$174K - $201K", "equity_range": "", "experience": "3+ years", "visa": "Will sponsor", "skills": [] }, { "id": 97725, "title": "Director, Office of the CEO, Founder in Residence Program", "url": "https://www.ycombinator.com/companies/billiontoone/jobs/l1CWVry-director-office-of-the-ceo-founder-in-residence-program", "location": "Menlo Park, CA, US", "type": "Full-time", "role": "Operations", "role_type": null, "salary_range": "$204K - $225K", "equity_range": "100.00%", "experience": "6+ years", "visa": "US citizen/visa only", "skills": [] } ], "news": [ { "title": "Molecular Diagnosis Firm BillionToOne Raises $273 Million in IPO - Bloomberg", "url": "https://www.bloomberg.com/news/articles/2025-11-06/molecular-diagnosis-firm-billiontoone-raises-273-million-in-ipo?taid=690c18284571d00001b66ed2&utm_campaign=trueanthem&utm_content=business&utm_medium=social&utm_source=twitter", "date": "Nov 05, 2025" }, { "title": "Diagnostics Firm BillionToOne Files for US IPO Despite Shutdown - Bloomberg", "url": "https://www.bloomberg.com/news/articles/2025-10-07/diagnostics-firm-billiontoone-files-for-us-ipo-despite-shutdown", "date": "Oct 07, 2025" }, { "title": "BillionToOne raises $130M at $1B-plus valuation for precision diagnostics", "url": "https://www.axios.com/pro/health-tech-deals/2024/06/21/billiontoone-130m-series-d-1b-valuation-precision-diagnostics", "date": "Jun 21, 2024" }, { "title": "BillionToOne Closes $125M Series C Funding with Premier Global Investors", "url": "https://www.linkedin.com/feed/update/urn:li:activity:6914924371232854017/", "date": "Mar 30, 2022" } ], "launches": [] }, { "id": 1235, "name": "Shield Bio", "slug": "shield-bio", "former_names": [ "TL Biolabs", "Shield Diagnostics" ], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://shieldbio.com", "all_locations": "San Francisco, CA, USA; San Jose, CA, USA", "long_description": "Shield Bio is a precision medicine company with a\r\nproprietary platform that enables reliable nanopore\r\nsequencing in under a minute, in a clinical setting. It is\r\nfocused on bringing 3rd generation or \"nanopore\"\r\nsequencing into clinical use to deliver on the promise of\r\nprecision medicine. Shield is initially using the technology to\r\nimprove the treatment of infectious disease and address the\r\nunmet clinical need of sepsis, which kills 300,000 people a\r\nyear in the US alone.", "one_liner": "Bringing 3rd generation, nanopore sequencing to healthcare to solve…", "team_size": 28, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1461210620, "tags": [ "Healthcare", "Genomics", "Nanotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2016", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/shield-bio", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2016/shield-bio.json", "year_founded": null, "city": "San Francisco", "country": "US", "linkedin_url": null, "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/tl-biolabs", "github_url": null, "logo_url": null, "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 135686, "full_name": "Fred Turner", "title": "Founder/CEO", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/fred-turner-70688776", "x_url": "https://twitter.com/FredTurnerBio", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/24846d3e66271106d7d5d967ea6f89429cc7313c.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1560, "name": "Helix Nanotechnologies", "slug": "helix-nanotechnologies", "former_names": [ "Helix Nanotechnologies" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/f05a634de42c2c96484608b63b33b99fd27aa56e.png", "website": "http://helixnano.com", "all_locations": "Boston, MA, USA; Cambridge, MA, USA", "long_description": "Technology finds information and delivers physical products to us almost instantly. mRNA does the same for biology. At HelixNano, we see a world where treatments are cheap, progress is decentralized, and you can modify biology at the push of a button.\r\n\r\nBy focusing on mRNA improvements from first principles, we’re getting there faster than we thought. Experiments that used to take months or years can be done in weeks and cost thousands instead of millions. The rate limiting step for our progress is now scientific curiosity.\r\n\r\nRigid hierarchies and top-down decisions will miss the magic. Some of our most powerful technologies started out as side projects of junior team members. At HelixNano, every individual scientist can have a massive impact on the company's direction. And the more diverse our team, the faster we’ll find the really cool ideas.\r\n\r\nWe've started rolling out some of our new tech — moving a COVID-19 vaccine candidate for the immunocompromised towards the clinic, and testing an intervention with massive environmental impact. But we’re scientists at heart, and team focus is solidly on the horizon.", "one_liner": "Next-generation mRNA platform to solve cancer, COVID and climate.", "team_size": 22, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1482443417, "tags": [ "Biotech", "Genomics", "Nanotechnology", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2017", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/helix-nanotechnologies", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2017/helix-nanotechnologies.json", "year_founded": null, "city": "Boston", "country": "US", "linkedin_url": "", "x_url": "http://twitter.com/helixnano", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/helixnano", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/f05a634de42c2c96484608b63b33b99fd27aa56e.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 173672, "full_name": "Nikolai Eroshenko", "title": "Founder/CSO", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/nikolai-eroshenko-668998119", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/f1d37eb73289b63509a03de868d65f0202150337.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1581, "name": "Sigma Genetics", "slug": "sigma-genetics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/3d163f0758d535d9b800f2a88bdefffc73c5bbe2.png", "website": "http://www.sigmagenetics.com", "all_locations": "Seattle, WA, USA", "long_description": "Sigma Genetics develops devices that can deliver DNA, RNA, and other charged molecules into cells by using magnetic fields. When compared to conventional electroporation, this technique has several key advantages, which include: the absence of arcing, the ability to scale, and the benefit of being non-invasive for in vivo applications. This platform technology can be applied to a wide range of applications- cell therapies, cancer drug delivery, DNA vaccines, biopharma manufacturing, and cosmetics.", "one_liner": "Sigma Genetics is a biotechnology company that is building…", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1492902064, "tags": [ "Biotech", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2017", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/sigma-genetics", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2017/sigma-genetics.json", "year_founded": null, "city": "Seattle", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/sigma-genetics-inc", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/3d163f0758d535d9b800f2a88bdefffc73c5bbe2.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 170639, "full_name": "Karen Eaton", "title": "Founder/CEO", "founder_bio": "Highly motivated to advance the healthcare field and I aspire to use both my business skills and scientific background to forward the medical industry. Interested in all things bio: cell/gene therapy, computational enzyme design, immunology, diagnostics, health devices, and so much more.", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/eatonkaren", "x_url": "https://twitter.com/DrKeaton", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/639e2f30bccf2012a5bb44fc4fa57df1c911803a.jpg" }, { "user_id": 171433, "full_name": "Matthew Scholz", "title": "Founder", "founder_bio": "Matthew is a serial entrepreneur with a background in gene therapy and computer security. He has founded or co-founded five biotechnology companies and has played an integral role in the development of several advanced therapeutics, including three first-in-class treatment modalities. He is the author of dozens of patents covering innovations ranging from novel transfection technologies, immune cell programming, in vivo production of therapeutic proteins, senolytics, longevity, and oncology.", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/matthewscholz", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/7b68855b254096395b46dc73e09be604599a469d.jpg" }, { "user_id": 3056, "full_name": "Chris Pihl", "title": "Founder", "founder_bio": null, "is_active": false, "linkedin_url": "https://www.linkedin.com/in/chris-pihl-4a84b1a/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/992f1901f2931a53242ae96e2364a9275135655f.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1686, "name": "Cambridge Cancer Genomics", "slug": "cambridge-cancer-genomics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/53b0518d38ef7cc187360951dee976ad809db1d9.png", "website": "http://ccg.ai", "all_locations": "Cambridge, England, United Kingdom; England, United Kingdom", "long_description": "CCG.ai exist to ensure that each patient has the right drug, at the right time, to beat their cancer.\r\n‍\r\nWe build the software to enable data-driven precision oncology and systematically develop data-driven biomarkers indicative of treatment response. We believe that increasing amounts of clinical and genomic data have the potential to transform cancer treatment, and enable oncologists to make smarter decisions about which drug to use in which circumstance.\r\n\r\nWe are expanding our team in Cambridge, UK, offering a fantastic opportunity for dedicated individuals who are comfortable in a high-work high-reward environment, and who are enthusiastic for a dynamic and varied role. We are looking for people who fit well into our team and company culture, and who like to overcome challenges and drive the business forward. In exchange, we offer a competitive salary with performance related bonuses and stock options, alongside excellent career development opportunities in a fast-growing start-up with a chance to truly impact how cancer is treated.\r\n\r\nTo apply, please send your CV to info@ccg.ai", "one_liner": "CCG.ai empowers clinicians to make personalised treatment strategies…", "team_size": 25, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1495670432, "tags": [ "Genomics", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2017", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United Kingdom", "Europe" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/cambridge-cancer-genomics", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2017/cambridge-cancer-genomics.json", "year_founded": 2015, "city": "Cambridge", "country": "GB", "linkedin_url": "", "x_url": "https://twitter.com/CCGenomics", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/cambridge-cancer-genomics", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/53b0518d38ef7cc187360951dee976ad809db1d9.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 195460, "full_name": "John Cassidy", "title": "Founder/CEO", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/john-w-cassidy", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/a09fdd7c7663987872a89785ed555287191901ac.jpg" }, { "user_id": 195868, "full_name": "Nirmesh Patel", "title": "Founder/Chief Scientific Officer", "founder_bio": "Scientist turned founder, trying to solve big problems and change the world!", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/nirmesh-patel/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/b95c957e6f36186997453224da349f1becbf6b67.jpg" }, { "user_id": 195908, "full_name": "Evaline Tsai", "title": "Founder/CPO", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/evaline-tsai-710b4386/", "x_url": "https://twitter.com/EvalineTsai", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/173c1510360021a6c88f401105de6a0a5c7df4aa.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1981, "name": "Coral Genomics", "slug": "coral-genomics", "former_names": [ "WeSeq" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/a6cfcb3e53947ed36f22a2c26c110aeb2434b48f.png", "website": "https://www.coralgenomics.com", "all_locations": "San Francisco, CA, USA", "long_description": "Coral integrates molecular, functional, and clinical factors to create new clinical laboratory tests that predict optimal treatments for autoimmune diseases.\r\n\r\nWe have also identified a unique subpopulation of patients who do not respond to current therapies and are working towards addressing this unmet medical need.", "one_liner": "New clinical tests for managing autoimmune treatments.", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1619016800, "tags": [ "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Acquired", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/coral-genomics", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2018/coral-genomics.json", "year_founded": 2018, "city": "San Francisco", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/a6cfcb3e53947ed36f22a2c26c110aeb2434b48f.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 246483, "full_name": "Atray Dixit", "title": "Founder", "founder_bio": "PhD from MIT and researched at Broad Institute", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/atray-dixit", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/59a1e3d0d660f1018a0ab6594e7f22e7cc89cb18.jpg" }, { "user_id": 252699, "full_name": "Jacob Borrajo", "title": "Founder", "founder_bio": null, "is_active": false, "linkedin_url": "https://www.linkedin.com/in/jacob-borrajo-1451735a/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/9ba559dad0ad5830dcb394d00b088a84d582088e.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 2029, "name": "Circumvent", "slug": "circumvent", "former_names": [ "Circumvent Pharmaceuticals" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/b5fd725fe8e2cac76ed87eacf3161d3f37da8f61.png", "website": "https://www.circumventpharmaceuticals.com/", "all_locations": "Portland, OR, USA", "long_description": "", "one_liner": "Utilizing monogenic disorders to inform and solve highly complex…", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1527534673, "tags": [ "Neurotechnology", "Biotech", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/circumvent", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2018/circumvent.json", "year_founded": null, "city": "Portland", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/circumvent-pharmaceuticals", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/b5fd725fe8e2cac76ed87eacf3161d3f37da8f61.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 247904, "full_name": "Devin Wiley", "title": "Founder", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/devinwiley/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/5ef0804235acc637ce72fb78b077e6cb84c0d850.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 12036, "name": "Probably Genetic", "slug": "probably-genetic", "former_names": [ "Aiwa Health" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/9558e9a7114240a3f1e2a6378bd906ffe21826f3.png", "website": "https://www.probablygenetic.com/", "all_locations": "San Francisco, CA, USA", "long_description": "Probably Genetic is changing the lives of patients living with severe, complex diseases. Our data platform is used by drug developers and patient advocacy groups to develop and launch treatments for these patients. Our technology discovers undiagnosed patients online, analyzes their disease state using machine learning and at-home testing, and enables compliant communication with patients. In doing so, we help patients access diagnoses, clinical trials, and treatments as early as possible.", "one_liner": "Patient Intelligence Platform for Genetic Disease ", "team_size": 17, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1541561609, "tags": [ "Health Tech", "Biotech", "Genomics", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Winter 2019", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/probably-genetic", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2019/probably-genetic.json", "year_founded": 2019, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/probablygenetic/", "x_url": "", "fb_url": "https://www.facebook.com/ProbablyGenetic/", "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/9558e9a7114240a3f1e2a6378bd906ffe21826f3.png", "app_video_url": null, "dday_video_url": null, "company_photos": [ "https://bookface-images.s3.us-west-2.amazonaws.com/attachments/3444e0738890168924b0ade38090a2fcb410e03f.png" ], "primary_partner": null, "founders": [ { "user_id": 272136, "full_name": "Lukas Lange", "title": "Founder", "founder_bio": "CEO & Co-Founder of Probably Genetic. Previously BCG & The Bill & Melinda Gates Foundation. PhD from Oxford as a Rhodes Scholar.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/lukas-lange-8b1aa334/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/a34d08ca7bd7d5ef817d25623cafb18ffa6f5ba1.jpg" } ], "jobs": [ { "id": 96645, "title": "Director of Strategic Partnerships", "url": "https://www.ycombinator.com/companies/probably-genetic/jobs/Q6sRPPm-director-of-strategic-partnerships", "location": "San Francisco / Remote (US)", "type": "Full-time", "role": "Sales", "role_type": null, "salary_range": "", "equity_range": "", "experience": "5+ years", "visa": "US citizen/visa only", "skills": [] }, { "id": 96647, "title": "Forward Deployed Product Manager", "url": "https://www.ycombinator.com/companies/probably-genetic/jobs/KPPjdYB-forward-deployed-product-manager", "location": "San Francisco", "type": "Full-time", "role": "Product", "role_type": null, "salary_range": "", "equity_range": "", "experience": "5+ years", "visa": "US citizen/visa only", "skills": [] } ], "news": [ { "title": "Probably Genetic raises $12M to scale rare disease dataset, support drug discovery", "url": "https://www.fiercehealthcare.com/health-tech/probably-genetic-raises-12m-scale-rare-disease-dataset-support-drug-discovery", "date": "Oct 14, 2026" } ], "launches": [] }, { "id": 12085, "name": "Volta Labs, Inc.", "slug": "volta-labs-inc", "former_names": [ "Volta Labs Inc." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/373e91d473569c304899f7cec638ddc0b46d10d6.png", "website": "http://voltalabs.com", "all_locations": "Boston, MA, USA; Cambridge, MA, USA", "long_description": "Volta Labs is a genomics applications company that has developed a cutting-edge digital fluidics platform to maximize performance and scalability of sample preparation in genomics while providing unparalleled consistency. Volta is transforming the way biological research and analyses are performed, allowing scientists to focus on what they do best -- pushing the boundaries of biology.\r\n\r\nAs a collective of scientists and builders working at the intersection of engineering and biology, we imagine a world where extracting vital information from biological samples is as simple as pressing a button. That's our vision, and we're turning it into reality.\r\n\r\nOur HQ is in Boston’s Seaport, where we develop and manufacture our technology. We believe in cross-functional collaboration and continuous learning – whether your interest is in biology, MechEng, CompEng, or simply joining a fast-growing startup striving to make the world a better place, we'd love to welcome you to our team. Check out some of our blog posts to learn more about work life at Volta. ", "one_liner": "Unlocking the utility of genomics for the world.", "team_size": 50, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1607278601, "tags": [ "Hard Tech", "Hardware", "Robotics", "Genomics", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Winter 2019", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": [ { "question": "Describe what your company does in 50 characters or less.\n", "answer": "We build Integrated circuits for biology workflows" }, { "question": "What is your company going to make? Please describe your product and what it does or will do.\n", "answer": "A high throughput automation system for Next-Generation Sequencing (NGS) sample preparation using digital microfluidic chip technology." } ], "question_answers": [ { "question": "How did your company get started? (i.e., How did the founders meet? How did you come up with the idea? How did you decide to be a founder?)", "answer": "In 2018, Volta Labs was born in the halls of MIT with a clear mission: to unlock the utility of genomics for the world.\\\\Previously nestled in the vibrant hub of Kendall Square, known as \"the most innovative square mile on the planet,\" we quickly became immersed in the dynamic biotech culture. After numerous conversations with other scientists and hours of research, we discovered that trailblazing biologists were being held back by the constraints of existing automation tools, particularly in the realm of DNA sequencing. While DNA readout technologies surged ahead, the upstream steps of sample preparation (sample prep) lagged behind.\\\\During Founder Udayan Umapathi’s graduate stint at the MIT Media Lab, what began as a humble printed circuit board to manipulate colorful droplets soon evolved into a solutionfor the notorious \"sample prep bottleneck.\" Propelled into action, we secured funding from top-tier VCs and got to work." }, { "question": "What's the history of your company from getting started until the present day? What were the big inflection points?", "answer": "Since the company was funded coming our YC in Winter 2019, our focus has been laser-sharp in the lab, where we've been busy inventing and constructing groundbreaking fluidic and sample manipulation technologies. We embrace an anti-disciplinary approach, tackling the toughest challenges by seamlessly integrating instrumentation, fluidics, software, biology, and chemistry. While we're currently channelling our energies into sequencing sample prep, our grand vision extends beyond – envisioning a future where a single universal machine automates the lion's share of biological workflows in genomics, proteomics, and synthetic biology.\\\\At Volta, we're not just shaping the future of genomics; we're engineering it. Join us in harnessing the power of biology and technology to change the world." }, { "question": "What is the core problem you are solving? Why is this a big problem? What made you decide to work on it?", "answer": "We are in the midst of a genomic revolution. From 1999 to 2000, the Human Genome Project generated the first “draft” human genome, which cost \\~$300 million across 20 labs worldwide. It took another three years, and hundreds of millions of dollars, to produce a human genome that was \\~90% complete, as complete as the technologies for sequencing DNA allowed at the time. In 2023, a scientist can sequence a genome at a bench for hundreds of dollars in a day. The adoption of sequencing technologies across new applications only continues to accelerate as it becomes easier, faster, and cheaper. \\\\Despite these advancements, preparing samples for sequencing remains a significant bottleneck. We believe that disruptive innovations are needed in sample prep to unlock the true utility of genomics. With the new reality of the $200 genome (sequencing cost alone), sample prep is becoming a more significant burden on labs than ever before. " } ], "url": "https://www.ycombinator.com/companies/volta-labs-inc", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2019/volta-labs-inc.json", "year_founded": 2018, "city": "Boston", "country": "US", "linkedin_url": "https://www.linkedin.com/company/volta-labs-inc", "x_url": "https://twitter.com/voltalabsinc", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/volta-labs-a9c8", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/373e91d473569c304899f7cec638ddc0b46d10d6.png", "app_video_url": null, "dday_video_url": null, "company_photos": [ "https://bookface-images.s3.us-west-2.amazonaws.com/attachments/b174dc71f1ac1b5b04ae4d55f5100d5bef2f19b8.png", "https://bookface-images.s3.us-west-2.amazonaws.com/attachments/7bb2e9324a7753b95d0c687a8a5d98b14165bf0a.png" ], "primary_partner": null, "founders": [ { "user_id": 11802, "full_name": "Udayan Umapathi", "title": "Founder", "founder_bio": "As the founder and CEO of Volta Labs, Inc., I have over five years of experience in creating and scaling a company that is transforming the field of sequencing sample prep. With a background in entrepreneurship, engineering, design and biology, I have a unique perspective and skill set that enables me to bridge the gap between different disciplines and domains.\n\nAt Volta Labs, we are building a disruptive product that streamlines the entire process of preparing samples for any sequencing technol", "is_active": true, "linkedin_url": "http://linkedin.com/in/udayanu/", "x_url": "https://twitter.com/uday1489", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/e36948027c0c8b60f053b0afec83af2bc19a7b3f.jpg" } ], "jobs": [], "news": [ { "title": "Volta Labs Launches Electrowetting-Based Automated NGS Sample Prep Platform | GenomeWeb", "url": "https://www.genomeweb.com/sequencing/volta-labs-launches-electrowetting-based-automated-ngs-sample-prep-platform", "date": "Feb 07, 2024" }, { "title": "Volta Labs and Integrated DNA Technologies Partner to Advance Target Enrichment Workflows", "url": "https://www.prnewswire.com/news-releases/volta-labs-and-integrated-dna-technologies-partner-to-advance-target-enrichment-workflows-302052365.html?tc=eml_cleartime", "date": "Feb 06, 2024" }, { "title": "Volta Labs and Watchmaker Genomics Partner to Simplify and Optimize NGS Library Prep", "url": "https://www.prnewswire.com/news-releases/volta-labs-and-watchmaker-genomics-partner-to-simplify-and-optimize-ngs-library-prep-302052367.html?tc=eml_cleartime", "date": "Feb 05, 2024" }, { "title": "Volta Labs Launches Callisto to Revolutionize Genomics and Sample Prep", "url": "https://www.prnewswire.com/news-releases/volta-labs-launches-callisto-to-revolutionize-genomics-and-sample-prep-302049915.html", "date": "Feb 01, 2024" }, { "title": "Volta Labs grabs $20 million to address a growing genomics bottleneck – TechCrunch", "url": "https://techcrunch.com/2022/03/18/volta-labs-grabs-20-million-to-address-a-growing-genomics-bottleneck/", "date": "Mar 18, 2022" } ], "launches": [ { "id": 78341, "title": "Volta Labs - A genomics applications company revolutionizing sample prep", "tagline": "Unlocking the utility of genomics for the world", "body": "**_tl;dr_** - Volta Labs introduces Callisto, a groundbreaking genomics sample preparation system. With its push-button simplicity, Callisto transforms sample prep unlike anything else in the past 15 years, offering a revolutionary and hands-free experience. Checkout the [**_product here._**](https://www.voltalabs.com/product)\n\n[Volta Labs](https://www.voltalabs.com/product) is a group of antidisciplinary scientists and builders working at the intersection of engineering and biology. With the release of Callisto, we brought to life a sequencer agnostic platform that spans from the raw biological sample to sequenceable molecules. We have done this by reinventing the full stack — hardware, software, chemistry, and biology. At Volta, we’re not just shaping the future of genomics, we are engineering it.\n\n![uploaded image](/media/?type=post&id=78341&key=user_uploads/11802/3c27fa33-e647-497c-997f-4c09284f47b6)\n\n\\\n[🤔](https://emojipedia.org/thinking-face) **The Problem** \n\nGenomic sequencing has made remarkable strides since its inception in 1990, with continuous advancements in both sequencing and data analysis over the past three decades. However, the process of preparing samples for sequencing has seen limited innovation during this time. Despite the tremendous progress in sequencing technologies, the sample preparation phase remains a bottleneck, often taking multiple days and requiring skilled lab technicians and expensive instruments.\n\n**✅ The Solution - The CallistoTM Sample Prep System**\n\nAt Volta, we aim to reduce time and complexity with the introduction of our flagship product, Callisto – a benchtop instrument with many pre-optimized applications that reduces operational requirements and costs in the laboratory and clinic that were previously cost-prohibitive. This innovation addresses the longstanding challenges that have hindered efficiency and accessibility in genomics, making it a game-changer for the industry.\n\n![uploaded image](/media/?type=post&id=78341&key=user_uploads/11802/ae8be7a4-5028-465f-a3f4-ea4d05dabc30)\n\n![uploaded image](/media/?type=post&id=78341&key=user_uploads/11802/da90f1f1-fd22-49a5-b025-5814ed501736)\n\n![uploaded image](/media/?type=post&id=78341&key=user_uploads/11802/c2fd28d3-6988-410b-a677-d20a6f0c1eae)\n\n**✨ Benefits**\n\nCallisto is set to revolutionize laboratories, seamlessly combining efficient nucleic acid extraction with push-button library creation. Explore some of the many advantages that Callisto introduces to the field of genomics sequencing:\n\n* Can be operated without specialized training and takes minutes to set up\n* Sequencer agnostic\n* All-in-one, benchtop solution that allows users to press start and walk away\n* Speeds up and simplifies both short- and long-read sequencing preparations\n* Out of the box, pre-optimized applications\n\n\n\n🤝 **Our Ask**\n\n* **Connect us with companies and individuals in life sciences and beyond.** Feel free to connect on [LinkedIn](https://www.linkedin.com/in/udayanu) or [send me an email directly](mailto:hello@voltalabs.co)\n* Volta is growing fast and looking for talented engineers as we ramp up production - software, mechanical and electrical. **Our immediate need is for a Software Engineering Lead, Electrical Lead and a Head of Manufacturing.**  [Apply here](https://www.voltalabs.com/careers) or [send me an email](https://hello@voltalabs.co) directly if you want to refer a friend.", "url": "https://www.ycombinator.com/launches/KNZ-volta-labs-a-genomics-applications-company-revolutionizing-sample-prep", "votes": 4, "created_at": "2024-02-12T03:20:46.409Z" } ] }, { "id": 12124, "name": "XGenomes", "slug": "xgenomes", "former_names": [ "XGenomes Corp." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/4cca3d33a3a643c65629ce3164548e924340e550.png", "website": "http://www.xgenomes.com", "all_locations": "Boston, MA, USA; Cambridge, MA, USA", "long_description": "At XGenomes, we are building a technology comprising novel biochemistry, hardware and algorithms for sequencing DNA. Our product will be streamlined: there is zero library preparation; we sequence directly on unadulterated single molecules of DNA; DNA extraction will be integrated with sequencing; there is no bioinformatics bottleneck. The sequence we produce will be of unprecedented accuracy due to several layers of in-built redundancy including the sequencing both strands of the double-helix concurrently. The sequence we produce will be complete, encompassing: structural as well as single nucleotide variants; long-range haplotype phase; the repetitive \"dark matter\" of the genome. The cost of goods (consumables) of sequencing will be <$10, which will allow us to price our product at a level that will help grow the market while still achieving >90% margin. We will start by offering access as a service to high value customers, which be followed by a razor and blade model of selling instruments and consumables. ", "one_liner": "XGenomes is building the sequencing technology of the future. ", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1541806492, "tags": [ "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2019", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/xgenomes", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2019/xgenomes.json", "year_founded": 2017, "city": "Boston", "country": "US", "linkedin_url": "https://www.linkedin.com/company/xgenomes/", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/xgenomes", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/4cca3d33a3a643c65629ce3164548e924340e550.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 288257, "full_name": "Kalim Mir", "title": "Founder/CEO", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/kalim-mir-b8037310/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/0b51af9445e755a37e17624146bfc8245767778e.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 12252, "name": "54Gene", "slug": "54gene", "former_names": [ "Stack Diagnostics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/f0d268f1433885c466eead20338651157ba4886f.png", "website": "http://www.54gene.com", "all_locations": "Lagos, LA, Nigeria; LA, Nigeria", "long_description": "We are an African genomics research, services and development company addressing the need to include under-represented African genomic data in research which could lead to medical breakthroughs and new healthcare solutions worldwide.", "one_liner": "Precision medicine for Africans and the global population", "team_size": 47, "industry": "Healthcare", "subindustry": "Healthcare -> Consumer Health and Wellness", "launched_at": 1543950224, "tags": [ "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2019", "status": "Inactive", "industries": [ "Healthcare", "Consumer Health and Wellness" ], "regions": [ "Nigeria", "Africa" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/54gene", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2019/54gene.json", "year_founded": null, "city": "Lagos", "country": "NG", "linkedin_url": "https://www.linkedin.com/company/54gene/", "x_url": "https://twitter.com/weare54gene", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/54gene", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/f0d268f1433885c466eead20338651157ba4886f.png", "app_video_url": null, "dday_video_url": null, "company_photos": [ "https://bookface-images.s3.us-west-2.amazonaws.com/attachments/fdd3cb70b507842ff97eb9cabfd00543282099b9.png" ], "primary_partner": null, "founders": [ { "user_id": 286369, "full_name": "Gatumi Aliyu", "title": "Founder", "founder_bio": "Chief Product officer Vendease (YC W21), Co Founder/Ex Chief Product Officer 54gene (YC W19)\n\n", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/gatumialiyu/", "x_url": "https://twitter.com/Uncle__G__", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/2a8c88a8c543755397d7ff113ef7ab0f79ba124b.jpg" }, { "user_id": 285188, "full_name": "Abasi Ene-Obong", "title": "Founder", "founder_bio": null, "is_active": false, "linkedin_url": "https://linkedin.com/in/abasieneobong", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/64852cc116ad6e63cda13480a9426a3bd05d6395.jpg" }, { "user_id": 287143, "full_name": "Ogochukwu Francis Osifo", "title": "Founder", "founder_bio": "", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/francisosifo", "x_url": "http://www.twitter.com/francisosifo", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/df3172543783f663e76d1741e471393624d6c559.jpg" } ], "jobs": [], "news": [ { "title": "54gene completes genetics study of 100,000 Nigerians to boost precision medicine - Businessday NG", "url": "https://businessday.ng/technology/article/54gene-completes-genetics-study-of-100000-nigerians-to-boost-precision-medicine/", "date": "May 10, 2022" }, { "title": "What 54gene actually does and why you should care, as told by COO, Delali Attipoe", "url": "https://techpoint.africa/2020/12/22/what-54gene-actually-does-delali-attipoe/", "date": "Dec 22, 2020" }, { "title": "54gene raises $15m from Bill & Melinda Gates-backed fund", "url": "https://qz.com/africa/1837527/54gene-raises-15m-from-bill-melinda-gates-backed-fund", "date": "Apr 14, 2020" }, { "title": "Only 2% of genomic material available for research comes from Africa; 54gene wants to change that • TechCrunch", "url": "https://techcrunch.com/2019/07/02/only-2-of-genomic-material-available-for-research-comes-from-africa-54gene-wants-to-change-that/", "date": "Jul 02, 2019" }, { "title": "54gene Raises $4.5 million to Create the World's First African DNA Biobank | TechCabal", "url": "https://techcabal.com/2019/07/02/54gene-raises-fund-create-african-dna-biobank/", "date": "Jul 02, 2019" } ], "launches": [] }, { "id": 12415, "name": "Spiral Genetics", "slug": "spiral-genetics", "former_names": [ "Spiral Genetics", "Inc." ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/822d8282aa459c05cf652eefd3f059118ec38f90.png", "website": "http://www.spiralgenetics.com", "all_locations": "Seattle, WA, USA", "long_description": "Spiral Genetics (YC W19) makes genomic data mining software to compare large populations of whole human genomes. Our customers are genetics testing companies, governments of countries, and pharma companies. We train our machine learning algorithms to enable large scale comparison of genomes to power novel discoveries, enabling new diagnostics and drugable targets.  ", "one_liner": "Large Scale Genomic Data Mining Software", "team_size": 7, "industry": "Healthcare", "subindustry": "Healthcare -> Healthcare Services", "launched_at": 1548889511, "tags": [ "Machine Learning", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2019", "status": "Inactive", "industries": [ "Healthcare", "Healthcare Services" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/spiral-genetics", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2019/spiral-genetics.json", "year_founded": 2009, "city": "Seattle", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/spiral-genetics", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/822d8282aa459c05cf652eefd3f059118ec38f90.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 309274, "full_name": "Adina Mangubat", "title": "Founder", "founder_bio": "Adina Mangubat is the CEO and co-founder of Spiral Genetics. Spiral Genetics makes software to compare large populations to enable novel drugs and diagnostics. She was featured in Forbes 2013 “30 Under 30″ for Science and Healthcare. In 2017, Forbes named her as one of the All-Star Alumni for the 30 Under 30 in Science and Healthcare. Adina is passionate about world-changing technology and having people be empowered to make the difference in the world that they are committed to making.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/amangubat/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/56c4057b642d5f829a8232449d313eaf07ab9446.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 12663, "name": "Arpeggio Bio", "slug": "arpeggio-bio", "former_names": [ "Arpeggio Biosciences" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/254b79d146cf6fc4b70498fed074d6743d577e13.png", "website": "http://www.arpeggiobio.com", "all_locations": "Boulder, CO, USA", "long_description": "Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted \"undruggable\" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success. ", "one_liner": "Arpeggio Bio develops drugs targeting transcription factors using AI…", "team_size": 20, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1556764311, "tags": [ "Biotech", "Genomics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2019", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/arpeggio-bio", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2019/arpeggio-bio.json", "year_founded": 2018, "city": "Boulder", "country": "US", "linkedin_url": "", "x_url": "https://twitter.com/ArpeggioBio", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/254b79d146cf6fc4b70498fed074d6743d577e13.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 326124, "full_name": "Joey Azofeifa", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/joey-azofeifa-060070130/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/e54ca8af79831aff4f578dbb2be13abee5368e30.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 12664, "name": "Kern Systems", "slug": "kern-systems", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/960f475f7529b916c176fbf83565873d60242a91.png", "website": "https://www.kernsystems.com", "all_locations": "Boston, MA, USA", "long_description": "DNA has emerged as a compelling data storage medium due to its density, longevity, and eternal relevance compared to current memory technologies. However, the high price of synthesizing DNA remains a major bottleneck for adoption of this promising storage solution. We are pioneering new approaches to synthesizing DNA for data storage with enzymes and custom digital codecs. We are building an interdisciplinary team to build the world's most scalable information infrastructure in DNA. \r\n\r\nWe seek technical experts in enzyme engineering, chemistry, hardware engineering, and information theory. We also seek business development to identify emerging markets for early use cases of our technology.", "one_liner": "Using DNA to store data.", "team_size": 3, "industry": "Healthcare", "subindustry": "Healthcare -> Industrial Bio", "launched_at": 1556764621, "tags": [ "Genomics", "Nanotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2019", "status": "Active", "industries": [ "Healthcare", "Industrial Bio" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/kern-systems", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2019/kern-systems.json", "year_founded": null, "city": "Boston", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/960f475f7529b916c176fbf83565873d60242a91.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 208492, "full_name": "Henry Lee", "title": "Founder", "founder_bio": "Interested in deep-tech. BS-EE@UW, PhD-BioE@BU, and Postdoc-Genetics@Harvard.", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/hhlee/", "x_url": "https://twitter.com/hhlee", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/df22de19c6b26415f0a25128aef33633f48ade68.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 12941, "name": "Sequence Bio", "slug": "sequence-bio", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/819f850ae7a7b60333fcb1b8a2c4ef4e8a3d2fd3.png", "website": "https://www.sequencebio.com/", "all_locations": "St. John's, NL, Canada", "long_description": "90% of drug candidates fail, delaying help for those in need. We’re on a mission to change that. Better drug target discovery powered by the Newfoundland founder effect.", "one_liner": "Discovering the true signals of disease to power life-changing drugs.", "team_size": 52, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1560967440, "tags": [ "Genomics", "Therapeutics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2019", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "Canada", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/sequence-bio", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2019/sequence-bio.json", "year_founded": 2013, "city": "St. John's", "country": "CA", "linkedin_url": "https://www.linkedin.com/company/sequencebioinformatics", "x_url": "https://twitter.com/sequencebio", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/sequence-bio", "github_url": "https://github.com/SequenceBio", "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/819f850ae7a7b60333fcb1b8a2c4ef4e8a3d2fd3.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 327968, "full_name": "Jeremy Grushcow", "title": "Founder", "founder_bio": "Ph.D. in Molecular Genetics and Cell Biology (University of Chicago, 2000); J.D. with Honors (University of Chicago Law School, 2003).\n\nPreviously: CBO, Sequence Bio S19 (Raised >$10m; LOIs signed with Sema4, Helix and Biogen); EVP, Strategic Development, Antibe Therapeutics (International partnerships, public company financings and disclosures; preclinical through Phase 1 for a novel pain therapeutic)\n\nBest dog dad ever; 7 out of 10 human dad.", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/jeremygrushcow/", "x_url": "https://twitter.com/crossborderbio", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/ff044c20376dd75fc72517397eda346a50760291.jpg" }, { "user_id": 323814, "full_name": "Chris Gardner", "title": "Founder", "founder_bio": null, "is_active": false, "linkedin_url": "https://www.linkedin.com/in/chriscgardner/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/1d75431e733272a4e4f7fa001c7dce0ed6443c81.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 13178, "name": "Felix Biotechnology", "slug": "felix-biotechnology", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/9f10efa48167c6eab9fc52d96d9bf7125ee15db7.png", "website": "https://www.felixbt.com/", "all_locations": "San Francisco, CA, USA", "long_description": "We are building the first end-to-end digital viral design platform to protect the world against the coming threat of antimicrobial resistance.", "one_liner": "We’re creating programmable therapies", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1584145927, "tags": [ "Biotech", "Genomics", "Therapeutics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Inactive", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/felix-biotechnology", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2020/felix-biotechnology.json", "year_founded": 2019, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/felixbt/", "x_url": "https://twitter.com/felixbiotech", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/felix-biotechnology", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/9f10efa48167c6eab9fc52d96d9bf7125ee15db7.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 427646, "full_name": "Robert McBride", "title": "Founder", "founder_bio": "", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/robcmcbride/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/6b2c0a59e970fbc429ff0495f6620ed3d61e3f05.jpg" }, { "user_id": 427662, "full_name": "Vivek Mutalik", "title": "Founder", "founder_bio": null, "is_active": false, "linkedin_url": "https://www.linkedin.com/in/vivekmutalik/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/1aa8d71d49eb498cb6bbc478b012c206cc32f440.jpg" }, { "user_id": 427747, "full_name": "Paul Turner", "title": "Founder", "founder_bio": null, "is_active": false, "linkedin_url": "https://www.linkedin.com/in/paul-turner-951bb072/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/051a0c9dff651ba619830ca7a3ee51d283a62127.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 13219, "name": "Dropprint Genomics", "slug": "dropprint-genomics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/8a62183607b4b9bdab50ebbf69002d2bc70f53e2.png", "website": "http://dropprintgen.com/", "all_locations": "San Francisco, CA, USA", "long_description": "Who we are?\r\nWe write software that understands the activity of individual cells as opposed to all cells. This approach is novel because we are no longer looking at average signals and can be precise. It is like a police person trying to identify the speeding car, they won’t find it if they look at all the cars at once, rather they need to look at the speed of each individual car. This is the beauty of single cell genomics, we can now identify that speeding car.\r\n\r\nWhy now?\r\nThe biggest barrier for entry into the single cell genomics market are cost and data analysis. To that end, we have reduced the cost by 10-fold and built the computational infrastructure for scalability. Although single cell sequencing has only been around for about five years, we come from one of the top single cell genomics labs and were the first to process and analyze millions of immune cells. Thanks to our software solutions, we have been able to bring big data solutions to the immune system.\r\n\r\nWhere are we and where are we going?\r\nWe have generated a database of over 1 million immune cells spanning healthy, cancerous, and autoimmune immune cells and are growing through paid partnerships. Harnessing out database and ML software, we can take a data-centric approach for better target discovery. Fortunately, as our database continues to grow, our models will continue to learn for more precise, unbiased, and automated single cell genomics.\r\n\r\nThank you! ", "one_liner": "The better way to run single cell genomics", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1583864374, "tags": [ "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Acquired", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/dropprint-genomics", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2020/dropprint-genomics.json", "year_founded": null, "city": "San Francisco", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/8a62183607b4b9bdab50ebbf69002d2bc70f53e2.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 343804, "full_name": "Rachel Gate", "title": "Founder", "founder_bio": "PhD bioinformatics (UCSF) | Cofounder of Dropprint Genomics (W20; acquired by Immunai) | Currently building out new businesses lines in biotech\n", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/rachelegate", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/d598c1aad7bf7ba807d7502d22cc8969a74940e6.jpg" }, { "user_id": 343369, "full_name": "Meena Subramaniam", "title": "Founder", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/meenasub/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/219705b7d5d4b4749a7bb6c2b826597fe48c2885.jpg" }, { "user_id": 343807, "full_name": "Jimmie Ye", "title": "Founder", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/chun-jimmie-ye-33a7666b/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/503ab0516c0d1ea16f1a4d64746349bf610dbe17.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 13672, "name": "Ochre Bio", "slug": "ochre-bio", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/d80993cda53fffe2cfd91762d630c27dc21561bf.png", "website": "https://www.ochre-bio.com/", "all_locations": "London, England, United Kingdom; Oxford, England, United Kingdom", "long_description": "Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases.", "one_liner": "RNA medicines for liver diseases", "team_size": 50, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1583988274, "tags": [ "Biotech", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2020", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United Kingdom", "Europe", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/ochre-bio", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2020/ochre-bio.json", "year_founded": 2019, "city": "London", "country": "GB", "linkedin_url": "https://www.linkedin.com/company/ochre-bio", "x_url": "https://twitter.com/OchreBio", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/d80993cda53fffe2cfd91762d630c27dc21561bf.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 420455, "full_name": "Quin Wills", "title": "Founder/CSO", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/quinwills/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/d5cf8bd0db814925b2c0f6271bb275be9de919f9.jpg" } ], "jobs": [], "news": [ { "title": "Boehringer signs $1.3B MASH collab with RNA biotech Ochre", "url": "https://www.fiercebiotech.com/biotech/boehringer-signs-13b-deal-rna-biotech-ochre-bio-team-tackle-mash", "date": "Apr 22, 2024" }, { "title": "RNA therapies startup Ochre Bio lands $30M to take on chronic liver disease - MedCity News", "url": "https://medcitynews.com/2022/10/rna-therapies-startup-ochre-bio-lands-30m-to-take-on-chronic-liver-disease/", "date": "Oct 10, 2022" }, { "title": "Oxford biotech raises funds to make RNA treatments for liver disease", "url": "https://www.ft.com/content/e4298d57-cdbb-4100-ada1-ddff5c9136a0", "date": "Oct 10, 2022" } ], "launches": [] }, { "id": 21881, "name": "Kernal Biologics", "slug": "kernal-biologics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/1534fd5c3c1e4705596c793a4a59a28da388bacf.png", "website": "https://www.kernalbio.com/", "all_locations": "Boston, MA, USA", "long_description": "Kernal Bio is a biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted cell delivery and minimal off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming within the body and resulting in B-cell depletion within a week.\r\n \r\nKernal Bio is led by a team with experience from MIT, Harvard, Merck, and BMS, boasting three FDA-approved therapies and over 120 patents. Based in Cambridge, MA, we are backed by Hummingbird Ventures, Amgen Ventures, HBM, and even NASA.\r\n\r\nWith roots at MIT, Harvard and Biopharma, Kernal’s management team has deep expertise in mRNA therapeutics space. CEO Yusuf Erkul, M.D., M.B.A. is a successful drug hunter whose research at Merck enabled an FDA-approved drug for ovarian cancer. President Burak Yilmaz, M.S., previously founded Sentegen, a thriving synthetic biology company which commercializes synthetic DNA, RNA, and diagnostic kits for genetic and infectious diseases. Sr. VP of R&D Manfred Kraus is a leader in immuno-oncology, who was most recently Scientific Sr. Director at Bristol-Myers Squibb (BMS). ", "one_liner": "Kernal is creating mRNA 2.0 therapies that work in specific cells", "team_size": 20, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1599762607, "tags": [ "Biotech", "Genomics", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2020", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/kernal-biologics", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2020/kernal-biologics.json", "year_founded": null, "city": "Boston", "country": "US", "linkedin_url": "https://www.linkedin.com/company/kernal-biologics-inc./", "x_url": "https://twitter.com/kernalbio", "fb_url": "https://www.facebook.com/KernalBiologics-1770335909881227/", "cb_url": "https://www.crunchbase.com/organization/kernal-biologics", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/1534fd5c3c1e4705596c793a4a59a28da388bacf.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Jared Friedman", "url": "https://www.ycombinator.com/people/jared-friedman" }, "founders": [ { "user_id": 241303, "full_name": "Yusuf Erkul", "title": "Founder", "founder_bio": "I'm co-founder and CEO of Kernal Biologics, a Boston-based biotech startup developing next-generation messenger RNA immunotherapy. Backed by Hummingbird, Amgen, Lilly, NVIDIA, HBM, NASA, and Boeing, Kernal Bio raised more than $30M. Early in my career, I worked at Merck&Co. on the discovery and development of various oncology drugs, including ZEJULA®, which got FDA approval for ovarian cancer. I hold an executive MBA from MIT Sloan, an M.D. from Hacettepe Univ. and a B.S. in Biology from MIT. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/yusuf-erkul-b23b4516/", "x_url": "https://twitter.com/yusuf_erkul", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/03c15c51cc4c1d4e920132e3e70fab69c28cf6a7.jpg" }, { "user_id": 253184, "full_name": "Jeff Ozdemir", "title": "Founder", "founder_bio": "I got PhD in Molecular Genetics at UTSW Medical Center at Dallas. I moved to Boston for postdoctoral training at Harvard Medical School. I served as Biochemistry instructor at MIT. Then I joined Kernal as a co-founder.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/jeff-ozdemir-phd-22822321/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/43dea221aa18943f65d05e7d16ea57ad94c5f2d6.jpg" }, { "user_id": 253237, "full_name": "Burak YILMAZ", "title": "Founder", "founder_bio": "My name is Burak Yilmaz, MS, co-founder, and lead designer of Kernal Biologics. As a synthetic biologist, I co-invented stealth and onco-selective mRNA platform technology in Kernal. Kernal is my second endeavor. Previously, I founded Sentegen/Sentebiolab which is a synthetic biology company that produces synthetic DNA for research and diagnostic purposes. ", "is_active": true, "linkedin_url": "http://linkedin.com/in/burak-yilmaz-84400730", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/9ddf422a1ee751e0c83309cb2702b20ab76b7001.jpg" } ], "jobs": [], "news": [ { "title": "Biotech startup Kernal Biologics received a $48 million", "url": "https://www.forbes.com/sites/innovationrx/2025/10/08/how-the-shutdown-impacts-healthcare/", "date": "Oct 07, 2025" }, { "title": "ARPA-H invests in Kernal's mRNA cell therapy", "url": "https://www.fiercebiotech.com/biotech/us-government-bankrolls-48m-kernals-mrna-car-t", "date": "Oct 07, 2025" }, { "title": "Kernal Bio Joins Lilly Gateway Labs to Accelerate In Vivo Cell Therapies", "url": "https://finance.yahoo.com/news/kernal-bio-joins-lilly-gateway-130000657.html", "date": "Oct 02, 2025" }, { "title": "Amgen-backed Kernal Biologics pops off with $25M for mRNA platform", "url": "https://www.fiercebiotech.com/biotech/amgen-backed-kernal-biologics-pops-25m-mrna-platform", "date": "Jul 07, 2022" } ], "launches": [] }, { "id": 23945, "name": "Talus Bio", "slug": "talus-bio", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6677b768e2a0c2a30de4f32fc3f4f2dce1baea6a.png", "website": "https://www.talus.bio", "all_locations": "Seattle, WA, USA", "long_description": "We have built a platform that enables drug discovery and development for previously undruggable genome regulators (\"the regulome\"). We accomplish this by moving drug discovery out of artificial systems where regulome proteins fail to function properly, and back into live human cells. Our technology combines innovations in automated cell processing, next-gen proteomics, and advanced data analytics to measure a drug's effect on the entire regulome in one experiment. ", "one_liner": "Discovering drugs that target the DNA regulome", "team_size": 16, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1629819925, "tags": [ "Biotech", "Genomics", "Drug discovery" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/talus-bio", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2021/talus-bio.json", "year_founded": 2020, "city": "Seattle", "country": "US", "linkedin_url": "https://www.linkedin.com/company/talus-bio/", "x_url": "https://twitter.com/talusbio", "fb_url": null, "cb_url": null, "github_url": "https://github.com/TalusBio", "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/6677b768e2a0c2a30de4f32fc3f4f2dce1baea6a.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Jared Friedman", "url": "https://www.ycombinator.com/people/jared-friedman" }, "founders": [ { "user_id": 352457, "full_name": "Alex Federation", "title": "Founder", "founder_bio": "I'm the co-founder of Talus Bio. Prior to Talus, I trained with Jay Bradner at Harvard in medicinal chemistry, drug screening, and drug development for gene regulators. After that, I moved to Seattle to continue my training in epigenomics and proteomics, and these were all combined to develop the Talus gene regulator platform.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/afederation/", "x_url": "https://twitter.com/afederation", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/5a8582d7e711e1ff2cc1556582a9b48e5e802997.jpg" }, { "user_id": 722621, "full_name": "Lindsay Pino", "title": "Founder", "founder_bio": "I'm Talus Bio's CTO, where my focus is on developing techniques for quantitative proteomics and in particular the challenges associated with scaling-up quantitative proteomics experiments. I’ve trained at the Broad Institute, the University of Washington, and most recently the University of Pennsylvania.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/lindsaykpino/", "x_url": "https://twitter.com/lkpino", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/1fd3365fa08bc96503fa616f9d45bf1af4e48fe4.jpg" } ], "jobs": [], "news": [ { "title": "Talus Bioscience lands $4.3M in grant funding for drug discovery platform – GeekWire", "url": "https://www.geekwire.com/2023/talus-bioscience-lands-4-3m-in-grant-funding-for-drug-discovery-platform/", "date": "Aug 18, 2023" }, { "title": "Inspired by scientist CEOs, Seattle startup lands $9.75M to build up drug discovery platform – GeekWire", "url": "https://www.geekwire.com/2022/inspired-by-scientist-ceos-seattle-startup-lands-9-75m-to-build-drug-discovery-platform/", "date": "Jun 06, 2022" }, { "title": "To turn off disease-causing genes, Talus Bio wants to knock proteins off of DNA | FierceBiotech", "url": "https://www.fiercebiotech.com/biotech/to-tackle-disease-causing-genes-talus-bio-takes-aim-at-proteins-switch-them-off", "date": "Aug 25, 2021" } ], "launches": [] }, { "id": 24369, "name": "Mable", "slug": "mable", "former_names": [ "Neurolytic Healthcare Ltd.", "Neurolytic Healthcare", "DiveHealth", "mable" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/1911bd76396413676c56a0b5104f3203eb60b44e.png", "website": "https://www.trymable.com/", "all_locations": "London, England, United Kingdom; San Francisco, CA, USA; Remote", "long_description": "Mable is a personalized migraine clinic using DNA to find and provide the right medication alongside continuous expert care\r\n\r\nUsing our approach, patients have an 80% higher treatment satisfaction rate, have one extra day per week to enjoy their life and get 55% pain reduction.\r\n", "one_liner": "First personalized migraine clinic using genetics and telehealth.", "team_size": 7, "industry": "Healthcare", "subindustry": "Healthcare -> Medical Devices", "launched_at": 1629725379, "tags": [ "Health Tech", "Telehealth", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Acquired", "industries": [ "Healthcare", "Medical Devices" ], "regions": [ "United Kingdom", "United States of America", "Europe", "America / Canada", "Remote", "Fully Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/mable", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2021/mable.json", "year_founded": 2019, "city": "London", "country": "GB", "linkedin_url": "https://www.linkedin.com/company/mable-health", "x_url": "https://twitter.com/mablehealth", "fb_url": "https://www.facebook.com/mablehealth", "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/1911bd76396413676c56a0b5104f3203eb60b44e.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 601243, "full_name": "Roman Rothaermel", "title": "Founder", "founder_bio": "Roman is a neuroscientist who has conducted several years of research on memory encoding in the brain, neuropharmacology and drug target characterization. During his PhD at Oxford University he uncovered a new mechanism causing brain-wide synchronization which is necessary for correct retrieval of complex memories. He also has an MSc in Neuroscience (Oxford, UK) and MSc in Biology (Tubingen, Germany).", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/rrothaermel/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/2a1183d55a4698be261fb91186c46313835f5b16.jpg" }, { "user_id": 601165, "full_name": "Inna Thalmann", "title": "Founder", "founder_bio": "Inna is Co-Founder and COO of Mable - a precision medicine company using whole genome sequencing to optimise prescribing decisions. Prior to this, Inna completed her PhD in Econometrics with a focus on Health Economics at the University of Oxford, followed by postdoctoral research focused on the development of novel phenotype algorithms to increase the cost-efficiency of clinical trials. ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/ithalmann/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/7f27e4e0778f740730693ac13d7fbcbc943401e3.jpg" } ], "jobs": [], "news": [ { "title": "Introducing Mable. Revolutionizing Migraine Care, through the Power of DNA.", "url": "https://www.trymable.com/blog/introducing-mable-revolutionizing-migraine-care-through-the-power-of-dna", "date": "Jul 27, 2022" } ], "launches": [] }, { "id": 24574, "name": "Genomelink", "slug": "genomelink", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/61c755cb25ac9262366c90a49a285fcd2783647e.png", "website": "https://genomelink.io/", "all_locations": "San Francisco, CA, USA; Remote", "long_description": "Genomelink is a DNA App Store. If you’ve taken a DNA test from Ancestry or 23andMe, you can upload your data to Genomelink to unlock a wide range of DNA apps: a 2,000+ region ancestry breakdown, insights from 400+ ancient DNA samples, analysis of 350+ genetic traits, unique DNA matches, and more.\r\n\r\nExplore our latest genealogy app, YourRoots (https://yourroots.com/), which transforms your family tree into an interactive global map visualization.\r\n\r\nWe believe consumer genomics today is where the internet was in the 1990s. Over 50 million people in the U.S. have already tested their DNA, and this number will grow into the billions globally in the coming decades. Genomelink aims to become the default DNA data hub and app store for this genomic future.\r\n\r\nOur mission:\r\n- Build the world’s #1 platform for consumer genomics apps\r\n- Help people discover their family roots and unite the world \r\n- Create an infruscrucure for consumer genomics", "one_liner": "DNA App Store", "team_size": 15, "industry": "Healthcare", "subindustry": "Healthcare -> Consumer Health and Wellness", "launched_at": 1624485672, "tags": [ "Consumer Health Services", "Genomics" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare", "Consumer Health and Wellness" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/genomelink", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2021/genomelink.json", "year_founded": 2017, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/genomelink", "x_url": "https://twitter.com/genomelink", "fb_url": "https://www.facebook.com/Genomelink/", "cb_url": "https://www.crunchbase.com/organization/awakens-inc", "github_url": "https://github.com/genomelink", "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/61c755cb25ac9262366c90a49a285fcd2783647e.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Jared Friedman", "url": "https://www.ycombinator.com/people/jared-friedman" }, "founders": [ { "user_id": 769086, "full_name": "Tomohiro Takano", "title": "Founder", "founder_bio": "Co-founder and CEO at Genomelink", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/tomohiro-takano-a0b3662a/", "x_url": "https://twitter.com/mr3tiago?lang=en", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/b57e7174e18f97f73416543e552dda0b7aa5faf6.jpg" }, { "user_id": 771271, "full_name": "Kensuke Numakura", "title": "Founder", "founder_bio": "Co-Founder and CTO of Genomelink", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/knmkr/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/92f6bf3c1b5f449db093449aead28ed83d77983f.jpg" } ], "jobs": [], "news": [ { "title": "YourRoots Map Launches: A New Way to Explore Your Family Tree on a Global Scale", "url": "https://yourroots.com/blog/yourroots-map-launches-a-new-way-to-explore-your-family-tree-on-a-global-scale", "date": "Jul 01, 2025" } ], "launches": [] }, { "id": 25350, "name": "Nest Genomics", "slug": "nest-genomics", "former_names": [ "Applied Genomics", "Guide Genomics", "Pepper Genomics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/c965d20fc0bacd98d8b38c9742848bdb11b05841.png", "website": "https://nestgenomics.com", "all_locations": "New York City, NY, USA; Remote", "long_description": "Nest is a lab-agnostic, comprehensive solution for organizations to launch and implement large-scale genomic programs. The platform includes the ability to triage, consent, and counsel patients for genetic testing, provide EMR-integrated clinical decision support for providers managing patients with genetic results, and manage patients’ clinical needs across the continuum of care.", "one_liner": "Software to launch and integrate genetics into clinical care", "team_size": 14, "industry": "Healthcare", "subindustry": "Healthcare -> Healthcare IT", "launched_at": 1648243110, "tags": [ "SaaS", "Health Tech", "Digital Health", "Genomics", "Primary Care" ], "tags_highlighted": [], "top_company": false, "isHiring": true, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Healthcare", "Healthcare IT" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/nest-genomics", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2022/nest-genomics.json", "year_founded": 2022, "city": "New York City", "country": "US", "linkedin_url": "https://www.linkedin.com/company/nesthealth", "x_url": "https://twitter.com/nestgenomics", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/c965d20fc0bacd98d8b38c9742848bdb11b05841.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Jared Friedman", "url": "https://www.ycombinator.com/people/jared-friedman" }, "founders": [ { "user_id": 123714, "full_name": "Moran Snir", "title": "Founder", "founder_bio": "I'm dedicated to increasing access to genetic information. My previous company Clear Genetics was acquired NVTA in 2019, where I led the Software and Data organization. I also founded MorNetware, which developed Genometer a software that screens 90% of Israeli pregnancies for ethnic-based carrier screening since 2005. I was an officer in the IDF Elite software unit and studied Biomedical Engineering for my BA M.Sc. I have an MBA from the Wharton Business School and am a 2-time Y Combinator Alum.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/moran-ronnie-shochat-snir-a29a23", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/a75e563c9e83bfc7bd25ce5721c1d85cf42f58df.jpg" }, { "user_id": 122091, "full_name": "Guy Snir", "title": "Founder/COO", "founder_bio": "I'm a co-founder and COO of Nest Genomics (W22). Until recently, I led SaaS teams at Invitae (NVTA), a global genetics company. I was the co-founder and COO of ClearGenetics (W17, acquired by Invitae), which developed innovative software for integrating genetics into routine care. Before that, I held senior product roles at Twitter, SnappyTV and Google/Motorola. I'm a Mammram Alum, hold a Bachelor’s in Computer Science and MBA from Duke and Tel-Aviv University.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/guysnir", "x_url": "https://twitter.com/guysnir", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/699ff919b3f8433e72027f68b696447c9e937d68.jpg" } ], "jobs": [ { "id": 49348, "title": "Sr. Fullstack Software Engineer", "url": "https://www.ycombinator.com/companies/nest-genomics/jobs/Ed46Kfp-sr-fullstack-software-engineer", "location": "United States / Remote (United States)", "type": "Full-time", "role": "Engineering", "role_type": "Full stack", "salary_range": "$160K - $180K", "equity_range": "", "experience": "6+ years", "visa": "US citizen/visa only", "skills": [ "GraphQL", "Node.js", "React", "TypeScript" ] } ], "news": [ { "title": "Genome Medical and Nest Genomics Partner to Scale Access to Genetic Services and Improve Patient Care", "url": "https://www.einnews.com/pr_news/777250665/genome-medical-and-nest-genomics-partner-to-scale-access-to-genetic-services-and-improve-patient-care", "date": "Jan 15, 2025" }, { "title": "Nest Genomics Joins athenahealth's Marketplace Program to Bring the Power of Genomics to the Point of Care", "url": "https://www.prnewswire.com/news-releases/nest-genomics-joins-athenahealths-marketplace-program-to-bring-the-power-of-genomics-to-the-point-of-care-302285905.html", "date": "Oct 23, 2024" }, { "title": "Nest Genomics Raises $8.5M to Increase Access to Patients’ Genetic Information - MedCity News", "url": "https://medcitynews.com/2023/01/nest-genomics-raises-8-5m-to-increase-access-to-patients-genetic-information/", "date": "Jan 10, 2023" }, { "title": "Nest Genomics Closes $8.5 Million Seed Financing to Bring Genomics into Mainstream Patient Care | Business Wire", "url": "https://www.businesswire.com/news/home/20230110005275/en/Nest-Genomics-Closes-8.5-Million-Seed-Financing-to-Bring-Genomics-into-Mainstream-Patient-Care", "date": "Jan 10, 2023" } ], "launches": [] }, { "id": 26311, "name": "WhiteLab Genomics", "slug": "whitelab-genomics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ba69864f65b85fda9f05c3280bc3b39f42500013.png", "website": "https://whitelabgx.com", "all_locations": "Paris, Île-de-France, France", "long_description": "WhiteLab Genomics is a TechBio company using artificial intelligence to design the building blocks of genomic medicines. Its proprietary ALFRED platform designs viral and non-viral delivery vehicles and programmable genetic payloads, which are then experimentally validated and tested in vivo to identify candidates with the properties required for therapeutic development. \r\n\r\nThrough this integrated approach, WhiteLab Genomics is building a portfolio of validated bio-assets that it advances independently and with pharmaceutical and biotechnology partners developing the next generation of genomic medicines.\r\n\r\nFounded in 2019, WhiteLab works with industrial and academic partners including Sanofi, Cytiva, the University of Massachusetts, the Vision Institute in Paris and the Paris Brain Institute, alongside additional collaborations with biotechnology companies. The company is part of Y-Combinator, Station F and Future4Care and is a French Tech 2030 laureate.\r\n\r\nWhiteLab Genomics operates from Paris, Boston, and Montreal.", "one_liner": "Unleash the potential of genomic medicine using AI", "team_size": 52, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1644584538, "tags": [ "Gene Therapy", "Cell Therapy", "Genomics", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "France", "Europe", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/whitelab-genomics", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2022/whitelab-genomics.json", "year_founded": 2019, "city": "Paris", "country": "FR", "linkedin_url": "https://www.linkedin.com/company/whitelabgenomics/", "x_url": "https://twitter.com/whitelabg?lang=en", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/ba69864f65b85fda9f05c3280bc3b39f42500013.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Nicolas Dessaigne", "url": "https://www.ycombinator.com/people/nicolas-dessaigne" }, "founders": [ { "user_id": 818146, "full_name": "David Delbourgo", "title": "Founder", "founder_bio": "23 y of experience in healthcare innovation with multiple executive roles in Business Development, Marketing and Commercial Operations.\nFormer GE Healthcare. MBA Chicago Booth, Biomedical Engineer MS University of Compiègne, France.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/daviddelbourgo/", "x_url": "https://twitter.com/DavidDelBourgo", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/c81c5cf739a324b1b2c85449e1553e6b4e509e6b.jpg" }, { "user_id": 847212, "full_name": "Julien Cottineau", "title": "Founder", "founder_bio": "Senior application scientist at Genomic Vision, leading provider of genetic devices and platform\nResearch fellow at Rockefeller Univ & Necker Hospital on human complex immune deficiencies in J-L Casanova’s lab\nPhD in genetics, molecular biology & immunology at Université Pierre & Marie Curie\u000bWith Honors\n", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/julien-cottineau-8a8b65112/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/e08d2afde8df9bb0f1975eb86f59b18a4ac2afa3.jpg" } ], "jobs": [], "news": [ { "title": "How WhiteLab Genomics is using AI to aid gene and cell therapy development • TechCrunch", "url": "https://techcrunch.com/2022/09/12/how-whitelab-genomics-is-using-ai-to-aid-gene-and-cell-therapy-development/", "date": "Sep 12, 2022" } ], "launches": [] }, { "id": 30937, "name": "Anto Biosciences", "slug": "anto-biosciences", "former_names": [ "Anto" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/83f56c369ac0fb5e70438516e774b8603717940a.png", "website": "https://www.anto.bio/", "all_locations": "San Francisco, CA, USA", "long_description": "Anto is building a foundation model for microbial communities, making the gut microbiome computable for the first time. We predict drug toxicity and efficacy across diverse populations and fix drugs so they work for everyone — solving the hidden root cause of most drug failures. \r\n\r\nFounded by Arvid (Broad Institute of MIT and Harvard; Nature-published researcher who pioneered quality-aware, goal-directed sparsification) and David (Harvard Medical School Gastroenterology, J&J), second-time founders who published the breakthrough at leading machine learning AI conferences and Nature. ", "one_liner": "A Foundation Model for Microbial Communities.", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare", "launched_at": 1761948352, "tags": [ "Generative AI", "Biotech", "Genomics", "Drug discovery", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Fall 2025", "status": "Active", "industries": [ "Healthcare" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/anto-biosciences", "api": "https://devasheeshg.github.io/yc-api/batches/fall-2025/anto-biosciences.json", "year_founded": 2025, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/anto-biosciences/", "x_url": "https://x.com/anto_f25", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/83f56c369ac0fb5e70438516e774b8603717940a.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Nicolas Dessaigne", "url": "https://www.ycombinator.com/people/nicolas-dessaigne" }, "founders": [ { "user_id": 1514534, "full_name": "Arvid E. Gollwitzer", "title": "Founder/CEO", "founder_bio": "Founder @ Anto Bio | Researcher @ Broad, Harvard, MIT | Lecturer @ ETH Zurich", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/arvid-gollwitzer/", "x_url": "https://x.com/arvidgollwitzer", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/c198f2ae79729c0ec59fbf566666e42e58082db3.jpg" }, { "user_id": 1361118, "full_name": "David de Gruijl", "title": "Founder/CTO", "founder_bio": "Co-founder @ Anto. Formerly Janssen Pharmaceuticals, ETH Zurich and Gastroenterology Dept. of BWH, Harvard Medical School. ", "is_active": true, "linkedin_url": "https://linkedin.com/in/daviddegruijl", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/b50bd83ae243af5006498387e9733112e4af827c.jpg" } ], "jobs": [], "news": [], "launches": [ { "id": 95292, "title": "Anto Biosciences: A Foundation Model for Microbial Communities", "tagline": "Making the microbiome computable. ", "body": "We’re [Arvid](https://www.linkedin.com/in/arvid-gollwitzer/) and [David](https://www.linkedin.com/in/daviddegruijl/), and we’re building [Anto Biosciences](https://www.linkedin.com/company/anto-biosciences).\n\n### tl;dr\n\nAnto is building a multimodal foundation model for microbial communities, making the gut microbiome computable for the first time. We predict drug toxicity and efficacy across diverse populations and optimize molecules for universal efficacy — addressing the microbiome-driven causes of drug response and failures.\n\n**Launch Video**: https://youtu.be/BDPp2wXiDbw\n\n### The Key Problem\n\n**We caught a cancer drug that worked in China but failed in U.S. trials. Same molecule, different microbiomes. $1B lost.**\n\nThis isn't an isolated story; more than a billion people are currently on medications where the microbiome dictates success or failure. The gut microbiome drives drug toxicity and efficacy, but pharma lacks the tools to understand and act on it \\[10,11,13\\]. Current methods to simulate the gut take months, cost millions, and rely on animal models that are too different from humans to be useful.\n\n### About Anto\n\n**We predict drug toxicity and efficacy across diverse populations and optimize molecules for broader efficacy—addressing the hidden, microbiome-driven causes of drug response and failures.**\n\nInput any drug molecule. We tell you how people will respond. We show where it works and where it fails—by geography, age, or diet.\n\nWe predict:\n\n* Population-specific efficacy (geographic, age-based, vegans vs. meat eaters, etc.)\n* Failure mechanisms (specific microbial metabolic pathways) \\[9,11\\]\n* Treatment response profiles across diverse populations \\[10,14\\]\n\nAnd we don't just flag risk; we identify failure mechanisms down to microbial metabolic pathways and generate treatment response profiles across populations. Then we optimize the molecule for broader efficacy. Turning 20% efficacy into 80% becomes an optimization problem we can actually solve.\n\n**Why we can do this:** We've pioneered quality-aware, goal-directed sparsification algorithms \\[5,9,15\\]. Microbiome data is 99% noise. We remove most of the noise and low-quality data through sparsification, leaving only the 1% that actually carries predictive power. That's how we make the microbiome computationally tractable. \\[6,7,8,14\\].\n\n### About Us\n\n[Arvid](https://www.linkedin.com/in/arvid-gollwitzer/) — Broad Institute of MIT and Harvard, ETH Zurich. Nature-published researcher who pioneered microbiome sparsification. Built the methods that make noisy microbial data tractable.\n\n[David](https://www.linkedin.com/in/daviddegruijl/) — ex-ETH Zurich, J&J, BWH, Harvard Med, Gastroenterology. Struggled with current drug digestion models firsthand. Knows where current workflows break and how to fix them.\n\n![uploaded image](/media/?type=post&id=95292&key=user_uploads/89898/3b2d64c2-dbc0-4bad-aad7-40b7995faeca)\n\nWe’re second-time founders who have lived this problem and published at leading AI conferences and Journals.\n\n### Traction\n\nWe're working with pharma R&D to simulate drug–microbiome interactions and de-risk cross-border deals with population-specific efficacy predictions and response profiles. Our open-source tools and research \\[1-9,14,15\\] are widely adopted and taught in engineering and computational biology programs \\[16\\].\n\n### What This Means for Digital / Computational Biology\n\n**The microbiome is the missing layer in drug development.** Most orally administered drugs are modified by gut bacteria before reaching their targets. We're making this layer computable for the first time \\[11-14\\].\n\nIf you're building in digital biology, precision medicine, or drug development, let's talk. The microbiome affects everything.\n\n### Our Asks\n\nIf you’re in drug development, cross-border deals, or translational medicine, we’d love to learn what microbiome requirements matter most to you. If you know teams in pharma and believe this product is cool, sharing / intros would mean a lot.\n\nIf you are in academia or microbiome research, try out our open-source tools \\[5-15\\]!\n\n**Get in touch**: [founders@anto.bio](mailto:founders@anto.bio) | [anto.bio](https://www.anto.bio/)\n\n### Our Research\n\nOur foundational work spans high-performance genomic analysis \\[1-4\\], metagenomic classification algorithms \\[5,9,14,15\\], in-storage computing for microbiome data \\[6-8\\], and the first large-scale datasets for causal modeling of microbial ecosystems \\[11,12\\]. We've pioneered techniques that make microbial communities computationally tractable, including quality-aware sparsification that reduces noise by 99% while preserving predictive power \\[5,9,15\\]. Our recent work on therapeutic resistance \\[10\\] and AI-controlled metagenomics for clinical applications \\[14\\] directly informs our drug optimization capabilities.\n\n**References:**\n\n\\[1\\] N. M. Ghiasi et al., \"GenStore: A high-performance in-storage processing system for genome sequence analysis,\" in _Proc. 27th ACM Int. Conf. Architectural Support for Programming Languages and Operating Systems_, 2022, pp. 635-654.\n\n\\[2\\] N. M. Ghiasi et al., \"GenStore: In-storage filtering of genomic data for high-performance and energy-efficient genome analysis,\" in _2022 IEEE Computer Society Annual Symposium on VLSI (ISVLSI)_, 2022, pp. 283-287.\n\n\\[3\\] N. M. Ghiasi et al., \"GenStore: A high-performance and energy-efficient in-storage computing system for genome sequence analysis,\" _arXiv preprint arXiv:2202.10400_, 2022.\n\n\\[4\\] M.-D. Rumpf, M. Alser, A. E. Gollwitzer et al., \"SequenceLab: A comprehensive benchmark of computational methods for comparing genomic sequences,\" _arXiv preprint arXiv:2310.16908_, 2023.\n\n\\[5\\] A. E. Gollwitzer et al., \"MetaTrinity: Enabling fast metagenomic classification via seed counting and edit distance approximation,\" _arXiv preprint arXiv:2311.02029_, 2023.\n\n\\[6\\] N. M. Ghiasi et al., \"MetaStore: High-performance metagenomic analysis via in-storage computing,\" _arXiv preprint arXiv:2311.12527_, 2023.\n\n\\[7\\] N. M. Ghiasi et al., \"MetaStore: High-performance metagenomic analysis via in-storage computing,\" _arXiv e-prints_, pp. arXiv-2311, 2023.\n\n\\[8\\] N. M. Ghiasi et al., \"MegIS: High-performance, energy-efficient, and low-cost metagenomic analysis with in-storage processing,\" in _2024 ACM/IEEE 51st Annual Int. Symp. Computer Architecture (ISCA)_, 2024, pp. 660-677.\n\n\\[9\\] A. Gollwitzer et al., \"MetaFast: Enabling fast metagenomic classification via seed counting and edit distance approximation,\" _arXiv preprint arXiv:2311.02029_, 2023.\n\n\\[10\\] A. E. Gollwitzer, D. A. Subramanian, I. Tucker, and G. Traverso, \"Steering the evolutionary game: Hierarchical control of therapeutic resistance in cancer treatment,\" in _NeurIPS 2025 AI for Science Workshop_, 2025.\n\n\\[11\\] A. E. Gollwitzer, D. A. Subramanian, I. Tucker, and G. Traverso, \"MetaOmics-10T: The foundational dataset to unlock causal modeling of microbial ecosystems,\" in _NeurIPS 2025 AI for Science Workshop_, 2025.\n\n\\[12\\] N. M. Ghiasi et al., \"MegIS: High-performance, energy-efficient, and low-cost metagenomic analysis with in-storage processing,\" _arXiv preprint arXiv:2406.19113_, 2024.\n\n\\[13\\] H. J. Haiser and D. de Gruijl, \"Emerging tools and technologies for microbiome-aware drug development,\" _Clinical Pharmacology & Therapeutics_, 2025, doi:10.1002/cpt.70026.\n\n\\[14\\] A. Gollwitzer et al., \"AI-controlled metagenomics: High-throughput taxonomic profiling for clinical pathogen detection and early-stage cancer screening and type classification,\" _arXiv preprint arXiv:2311.02029_, 2025.\n\n\\[15\\] A. Gollwitzer et al., \"The Thinking Microscope: A reinforcement learning framework for the co-optimization of computational and generative data sparsification in metagenomics,\" _arXiv preprint arXiv:2311.02029_, 2025.\n\n\\[16\\] A. E. Gollwitzer, \"Decoding the human microbiome through AI-controlled metagenomics: Promises and ethical implications,\" presented at ETH Zurich ETHix Series, Dec. 2024. \\[Online\\]. Available [here](https://bioethics.ethz.ch/news-and-events/news-bioethics/2024/12/decoding-the-human-microbiome-through-ai-controlled-metagenomics-promises-and-ethical-implications.html).", "url": "https://www.ycombinator.com/launches/Omy-anto-biosciences-a-foundation-model-for-microbial-communities", "votes": 32, "created_at": "2025-11-07T20:30:08.883Z" } ] }, { "id": 33016, "name": "Gamgee", "slug": "gamgee", "former_names": [ "Gamgee Technologies" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6f6bf83f60f82f47f1a3b961153608810edebb3b.png", "website": "https://gamgee.io/", "all_locations": "San Francisco, CA, USA; Remote", "long_description": "​Gamgee began with Rosie, founder Paul Conyngham’s dog. After surgery, chemotherapy and immunotherapy failed, Rosie was given months to live. Paul used AI and genomic analysis to identify targets in her tumour, then worked with scientists at UNSW to produce what is believed to be the first fully computationally designed mRNA cancer vaccine delivered to a dog. Following treatment, several tumours shrank significantly and her quality of life improved\r\n\r\nGamgee is building an end to end platform for personalised mRNA cancer vaccines for dogs. We sequence a dog’s tumour and healthy DNA, identify mutations unique to its cancer, and design a vaccine that teaches the immune system what to attack. We manage the entire process- from vet intake and tissue collection through genomic analysis, vaccine production, treatment and response monitoring\r\n\r\n​We are now turning that one off effort into a repeatable clinical system. Gamgee is running clinical trials in Australia, working with vets, oncologists and specialised laboratories, and accepting cases globally. Our goal is to make personalised cancer treatment accessible to every dog that needs it- and use each case to improve the treatment for the next", "one_liner": "Curing cancer. Starting with dogs.", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1784748212, "tags": [ "Biotech", "Genomics", "Oncology", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2026", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/gamgee", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2026/gamgee.json", "year_founded": 2026, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/109672135", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/6f6bf83f60f82f47f1a3b961153608810edebb3b.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Tyler Bosmeny", "url": "https://www.ycombinator.com/people/tyler-bosmeny" }, "founders": [ { "user_id": 564809, "full_name": "Paul Conyngham", "title": "Founder/CEO", "founder_bio": "Founder at Gamgee Technologies (YC S26), building personalised mRNA cancer vaccines for dogs.\n\nGamgee grew out of my work using AI and genomics to help my dog Rosie fight cancer. \n\nPreviously co-founded Core Intelligence, building applied AI systems across startups and enterprise, and helped grow Australia’s AI community as a founding member of the Data Science & AI association of Australia. \n\nBackground in ML, data science and electrical and computer systems engineering", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/paustevenlconyngham/", "x_url": "https://x.com/paul_conyngham", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/4fda91993052b2e444cfffa9d59e27aa42567028.jpg" } ], "jobs": [], "news": [], "launches": [ { "id": 109527, "title": "Gamgee: Personalised mRNA cancer vaccines for dogs", "tagline": "Input the tumour. Output the vaccine. 300+ dogs on the waitlist.", "body": "**We believe that AI meets biology is the biggest opportunity of the 21st century.** We are using AI to build autonomous systems that read biological failure, discover how to control it, and design precise repairs. We are starting with the first computationally personalised mRNA cancer vaccine for dogs.\\\n\\\n**My dog Rosie was dying of cancer.** I designed her an mRNA vaccine. Several of her tumours shrank 50-75%. I am not a biologist - I spent 17 years in machine learning. Doing it by hand took a year and around $20,000. Gamgee is turning that process into software. Our target is a vaccine design in 48 hours and an end-to-end cost of $2,000\n\n\n\n**How it works**\n\n* We **send you a collection kit** to take to your vet or veterinary oncologist. Your vet collects the tumour and matched healthy samples, which are returned for DNA and RNA sequencing.\n* Our software finds and ranks the mutations worth targeting, and keeps the evidence behind every call.\n* **Out comes an mRNA vaccine** design ready for manufacture. Gamgee designs the vaccine and oversees and coordinates every step through to administration by the treating veterinarian.\n\n\\\n**The market**\n\nApproximately **six million dogs** are **diagnosed with cancer** every year in the United States, and cancer is the leading cause of death in adult dogs. Owners who pursue specialist treatment spend thousands on surgery, chemotherapy and radiation.\\\n\\\n\\\n**The compounding data advantage**\n\nEvery dog we treat returns sequencing, immune and outcome data for a species where datasets remain scarce. That data improves target selection, which improves the next vaccine, which produces better data. We are not just early to the problem - we are the ones accumulating the data that solves it.\n\n\\\n**Proof so far**\n\n* Full computational pipeline built and executed end-to-end as a non-biologist using AI\n* 50-75% shrinkage in the responsive tumours. \n* Microscopic analysis found substantial IBA1+ macrophage and CD3+ T-cell infiltration in Rosie’s responsive lesions, with little in the non-responsive tumour.\n* Second-generation vaccine completed and ready\n* Over a billion impressions on Rosie's story.\n* Backed by Y Combinator (S26) \n\nRosie was one patient. Our next step, already well underway, is a clinician-led trial in 30 dogs to evaluate safety, immune response and clinical outcomes.\n\n\\\n**Why dogs first, and not only dogs**\n\nMost modern dog breeds were created within the last few hundred years from small founder populations and then bred within closed gene pools. This concentrates inherited cancer risk, leaving many breeds unusually prone to particular cancers.\\\n\\\nPet dogs develop cancer naturally, not in a laboratory. Their immune systems are intact and their disease progresses on timelines that let us learn quickly. Dogs are a real market in their own right and the fastest place to get good at personalised cancer vaccines.\n\n\\\n**Our ask**\n\n* **If your dog has cancer, please do get in touch about our upcoming clinical trial.**\n* Veterinary oncologists and specialty hospitals who want to be a trial site.\n* Investors in longevity or personalised medicine - would rather meet you before the trial reads out than after.\n\nWe are building Gamgee so that no other dog waits for hope which arrives too late.\n\nReach me at [paul@gamgee.io](mailto:paul@gamgee.io) or [gamgee.io](http://gamgee.io)\\\n\\\nI love you Rosie.", "url": "https://www.ycombinator.com/launches/SUZ-gamgee-personalised-mrna-cancer-vaccines-for-dogs", "votes": 186, "created_at": "2026-08-11T17:00:00.187Z" } ] } ]